Imugene (IMU) Stock Price, News & Analysis

Company Overview

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 12.70 million shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: 3.03%
• Price Target: N/A
• Consensus Rating: N/A

IMU Stock Analysis - Frequently Asked Questions

How were Imugene's earnings last quarter?

Imugene Limited (ASX:IMU) issued its earnings results on Thursday, February, 28th. The company reported $0.00 earnings per share (EPS) for the quarter.

What other stocks do shareholders of Imugene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Imugene investors own include Meta Platforms (META), NVIDIA (NVDA), Precision BioSciences (DTIL), Fortescue (FMG), Teladoc Health (TDOC), Viralytics (VRACY) and Whitehaven Coal (WHC).

Company Calendar

• Last Earnings: 2/28/2019
• Today: 11/21/2024

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: ASX:IMU
• CUSIP: N/A
• CIK: N/A
• Web: www.imugene.com
• Phone: 61 3 9824 5254
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-149,680,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -97.23%
• Return on Assets: -50.88%

Debt

• Debt-to-Equity Ratio: 1.08
• Current Ratio: 3.86
• Quick Ratio: 15.17

Sales & Book Value

• Annual Sales: $4.97 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 3.75
• Book Value: A$0.02 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 7,570,000,000
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 3.34